Company Name, Ticker, Customers, else..

Valuation Comparisons

Management Effectiveness

• ROA Quarterly

• ROI Quarterly

• ROE Quarterly

Financial Strength

Dividend Comparisons

Integrated Biopharma Inc (INBP)

Other Ticker:

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Integrated Biopharma Inc's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Return On Equity	(Dec 31 2022) II. Quarter	(Sep 30 2022) I. Quarter	(Jun 30 2022) IV. Quarter	(Mar 31 2022) III. Quarter	(Dec 31 2021) II. Quarter
Y / Y Equity Change	16.07 %	25.05 %	29.59 %	74.12 %	-
Y / Y Net Income Change	-	-	-66.85 %	-35.78 %	-15.77 %
Net Income (TTM) in Millions	2	3	4	7	7
Return On Equity (TTM)	12.09 %	18.72 %	23.08 %	44.01 %	53.01 %
Total Ranking	# 1071	# 825	# 773	# 311	# 269
Equity (TTM) in Millions	19	19	19	17	16
Seq. Equity Change	0.17 %	0.25 %	9.43 %	5.63 %	7.92 %
Seq. Net Income Change	-	-	87.45 %	-22.7 %	99.81 %

Back to INBP Management Effectiveness >> INBP's 5 Years Annual ROE >> Compare INBP ROE to its Competitors

Roe Comment

Integrated Biopharma Inc returned in II. Quarter 12.09 % on shareholder's equity, that was lower than company average return on equity.

ROE decreased compare to previous quarter, due to detoriation of net income.

Within Healthcare sector 92 other companies have achieved higher return on equity. While Return on equity total ranking has deteriorated compare to previous quarter from 825 to 1071.

What is ROE?

Return On Equity Company Ranking
Within:	No.
Industry	# 35
Sector	# 93
Overall	# 1081

Return On Equity Statistics
High	Average	Low
171.24 %	76.29 %	12.09 %
(Jun 30 2019)		(Dec 31 2022)

INBP Annual Return On Equity	(Jun 30 2022) 2022	(Jun 30 2021) 2021	(Jun 30 2020) 2020	(Jun 30 2019) 2019	(Jun 30 2018) 2018
Total Equity in Millions	19	14	6	2	-5
Y / Y Equity Change	29.59 %	136.26 %	220.5 %	-	-
Net Income in Millions	4	8	4	2	1
Y / Y Net Income Change	-52.1 %	95.06 %	143.36 %	88.6 %	-64.78 %
Return On Equity	20.66 %	55.9 %	67.71 %	89.17 %	-

Back to INBP Management Effectiveness >> INBP's 5 Years Annual ROE >> Compare INBP ROE to its Competitors

Annual Roe Comment

In 2022 ROE decreased compare to previous year to 20.66 %, due to detoriation of net income.

Financial Statements
Integrated Biopharma Inc's Equity	$ 19 Millions	INBP's Balance sheet
Integrated Biopharma Inc's Income	$ 0 Millions	Quarterly INBP's Income Statement
INBP's Income by Division		See INBP's Income by Division

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
Roe Trends for overall market
INBP's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Roe for INBP's Competitors
Return On Equity for Integrated Biopharma Inc's Suppliers
Roe for INBP's Customers

You may also want to know
INBP's Roa	INBP's Inventory Turnover Ratio	INBP's Growth Rates	INBP's Dividend Statistics
	INBP's Profitability Ratios	INBP's Asset Turnover Ratio	INBP's Dividend Growth
INBP's Roi	INBP's Valuation Ratios	INBP's Financial Strength Ratios	INBP's Dividend Payout Ratio

Companies with similar Return On Equity at Dec 31 2022, within Healthcare Sector	ROE
Merck and Co Inc	33.23 %
Carlisle Companies Incorporated	31.81 %
Singular Genomics Systems Inc	31.55 %
Ironwood Pharmaceuticals inc	30.52 %
Bruker Corporation	29.20 %
Inmode Ltd	29.12 %
Precigen Inc	28.44 %
Hologic Inc	28.26 %
Semler Scientific Inc	27.54 %
Vertex Pharmaceuticals Inc	26.69 %
Edwards Lifesciences Corporation	25.56 %
Vir Biotechnology Inc	25.22 %
Agilent Technologies inc	25.05 %
Johnson and Johnson	24.14 %
Biogen Inc	24.06 %
West Pharmaceutical Services Inc	23.66 %
Resmed Inc	23.44 %
Pactiv Evergreen Inc	23.25 %
Quidelortho Corp	23.12 %
Corcept Therapeutics Inc	22.20 %
Gilead Sciences Inc	22.17 %
Lftd Partners Inc	21.76 %
Siga Technologies Inc	20.84 %
Msa Safety Incorporated	20.74 %
Regeneron Pharmaceuticals Inc	20.49 %
Bristol myers Squibb Company	19.80 %
Iqvia Holdings Inc	19.50 %
Synaptogenix Inc	19.35 %
Ufp Technologies Inc	19.21 %
Abbott Laboratories	19.11 %

Date modified: 2023-02-11T17:18:05+00:00


Economy Advance Monthly Sales Consumer Price Index CPI Producer Price Index PPI Retail Inventories Personal Income Gross Domestic Product GDP Money Supply Industrial Production Productivity Employment Situation US International Trade Factory Orders Durable Goods Construction Spending Housing Starts Vehicle Unit Sales	Stocks Event Calendar AFMD's Profile Stock Price AFMD's Financials Business Description Fundamentals Charts & Quotes AFMD's News Suppliers AFMD's Competitors Customers & Markets Economic Indicators AFMD's Growth Company Segments	Screening Stock Performance Growth Rates Profitability Valuation Dividend Financial Strength Efficiency Largest Companies Management Effectivness

Help

Sitemap

Advertise

About us

Glossary

Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071